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Introduction
Simply saying, inventions represent new solutions to
technical problems. The word “technique” means “re-
straining of natural forces and controlled use of natural
phenomena” 
1, that is “human activity in the field of mate-
rial phenomena characterized by space, time, matter and
energy” 
2. Thus, the technique is, actually, human activity
to master and control nature. Once the domain of technique
was confined to nonliving nature. Yet, today, it has been
considered that technique also comprises  the activities in
the field of living beings, although the patent law protec-
tion cannot be realized in domain of those  biological proc-
esses which cannot be influenced, that is, controlled in a
way that their repetition under same conditions would yield
the same results 
3.
There are two basic types of inventions: inventions of
products and inventions of processes. These are the products
and processes that have never been comprised in the state of
the art (they have never been exposed to public in any form).
The particular sorts of inventions are inventions of use. They
refer to the technical instructions as for the manner of appli-
cation of an already existing product, or an already known
process, but for a new technical purpose 
4.
The inventions are generally protected by patent law,
but not all of them. There are three groups of inventions that
cannot be legally protected: the commercial application of
which would be contrary to "ordre public" or morality; re-
lated to methods for treatment of the human or animal body
by surgery or therapy and diagnostic methods practiced on
the human or animal body; related to plant and animal varie-
ties or essentially biological processes for the production of
plants or animals.
The inventions of the products such as substances or
compositions used for diagnostic, surgical and healing pur-
poses are not excluded from patent protection. In other
words, the inventions related to drugs and medical means can
be registered as patents.
A patent constitutes a set of exclusive rights granted to
the inventor in a sense that they prevent others to exploit the
patented invention without permission – though not for an
indefinite period of time, but usually for the period of 20
years. The exceptions are the inventions of human and ani-
mal drugs and medicines whose term of protection may be
extended if their sale has to be previously authorized and ap-
proved by relevant government bodies.
This article is divided in three parts. The first part deals
with the inventions of surgery, therapy and diagnostic methods
applied to humans and animals. The second part, considers the
patents for invention of products (i.e. drugs and medical
means) in surgery, therapy and diagnostic to be used in sur-
gery, methods applied on humans and animals. Finally, the
third part, reviews the issue of the extended term of patent
protection for inventions of drugs for humans and animals.
Exclusion of certain medical methods from patent
protection
There is still widely spread opinion that granting the
patent rights for inventions in the field of medicine would be
inappropriate and against the general concept of health pro-
tection. Therefore, it has been decided that patent rights can-
not be granted for inventions related to surgical, diagnostic
and treatment procedures.
A surgical method, according to the patent law, is a
method of cutting and removing a living tissue of the hu-Volumen 70, Broj 6 VOJNOSANITETSKI PREGLED Strana 601
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man or animal body. Cutting and removing of living tissue
can be performed in a classical way, with knife, or by ap-
plying lasers, high-frequency electrodes, etc. Therefore, the
exclusion of surgery method inventions involving cutting
and removing of living tissue from patent protection refers
to both invasive and non-invasive procedures. The inven-
tion of surgery methods are excluded from patent protec-
tion if maintaining life and health of treated subjects is of
paramount importance for the performed intervention. Cor-
respondingly, invention of plastic surgical methods such as
transplantation of skin burnt in an explosion cannot be pat-
ent protected. On the other hand, the invention of methods
such as hair cutting, wool sheering, depilation, nail trim-
ming, horseshoeing, although involving cutting and re-
moving of human or animal living tissue, are not excluded
from patent protection.
In pursuance of the patent law, a diagnostic method is a
method used to identify the health condition of an organism.
A diagnostic method includes several phases: examination of
health condition, data collecting, data comparison, identifi-
cation of a disorder and, finally, deductive clinical decision
phase. Diagnostic method invention is excluded from patent
protection only if all the abovementioned phases are present.
If only one of these constituent phases of the diagnostic
method is missing, the entire method is not considered to be
diagnostic, but only a procedure that can be used in diagnos-
tics
5. Additionally, the exclusion is only applied where a di-
agnostic method made it immediately possible to decide on a
particular course of medical treatment. But if application of a
diagnostic method provides only interim or preliminary re-
sults (e.g. methods of internal imaging such as magnetic
resonance imaging or methods for measuring temperature),
method invention is patentable.
According to the patent law, a therapy method is a
method of eliminating or alleviating a disease where the term
disease is defined in the patent law as "all, even slight and
passing, abnormal activities of the human body which ex-
ceeds the standard tolerance level and/or significant and not
perishable deviation from standard human experience and
perception"
6 (the term disease is differently defined in the
patent law, labour law or health insurance law). Therefore,
the method of therapy considering the patent law does not re-
fer to the medical treatment that is eliminating or alleviating
of some ailments or problems which are not considered to be
a disease (e.g. fatigue, blackheads, etc). Also, therapy meth-
ods in the sense of the patent law do not include medical
treatments undertaken for cosmetic, dietary, hygienic or
sanitary purposes (e.g. coloring, straightening/curling, regen-
eration or promoting hair growth; skin lifting, pregnancy
testing, contraception, sweat removing or breath refreshing,
etc)
6. Both preventive and curative treatments fall within the
meaning of "therapy" and are therefore excluded 
7.
The inventions of surgery, therapy and diagnostic
methods are excluded from the patent protection only in
cases when the invented method is applied to the living hu-
man or animal body. This means that the exclusion does not
apply, and the patent rights could be granted for the same
method if it is applied to the corpse, or on the living tissue
which is separated from the human or animal body (for ex-
ample, bone marrow, blood, biopsy samples, etc.).
As for the justification of excluding the inventions of
surgery, therapy and diagnostic methods from granting the
patent rights, legal scholars and theoreticians have contra-
dictory opinions and stands. Some believe that the reasons
for this exclusion should be sought in a traditionally reserved
stand related to awarding the patent rights for the inventions
in domain of health protection, and as such, they are out-
dated
2. On the other hand, some believe that the exclusion of
the inventions of surgery, therapy and diagnostic methods
from patent protection is justifiable since it prevents the pat-
ent system to constrain the freedom of doctors in how they
treat patients 
8. In other words, this legal solution excludes a
possibility that saving a person’s life by applying a particular
surgical method may depend on the will of the inventor’s
monopolistic right over that method 
9.
Patent protection for inventions of drugs and
medical means
Even when all conditions for the exclusion of surgery,
therapy and diagnostic methods inventions from awarding
the patent rights have been fulfilled, still the inventions of
the substances and compositions applied in such methods can
be protected by patents. This means that the inventions re-
lated to medical equipment, instruments and disability aids,
as well as drugs can be the subject of patent protection.
Patent protection for drugs is a newer issue in our pat-
ent law history reflecting the interests of leading global
pharmaceutical companies to secure profit given their enor-
mous research and development investments. Allowing the
possibility of patent protection of drugs and medical means
has diminished the significance of ethical reasons for the ex-
clusion of all inventions in the field of medicine from patent
protection. This is supported by the fact that out of 56 billion
dollars invested annually in medical research, less than 10%
of this amount is dedicated to inventing new drugs for treat-
ing diseases affecting 90% of global population.  In other
words, the research and development efforts in pharmaceuti-
cal industry are mostly directed into inventing new drugs for
the treatment of cardiovascular diseases, the diseases of cen-
tral nervous system and diuretics 
10. In the period between
1975 and 1997, out of 1,223 newly patented substances or
compositions for use in pharmacy, only 11 were related to
the treatment of tropical diseases 
11.
Although the industrial production of drugs started in
1896 when the first tablet press, a machine compressing
powder into tablets was introduced in Germany, it has been
considered that modern pharmaceutical industry started with
the introduction of sulfonamide in 1935 
12. The development
of pharmaceutical industry has rapidly continued ever since
and today this industry is among the most innovative linking
chemical industry, biotechnology and medicine. Contempo-
rary pharmaceutical industry is characterized by a large so-
cial significance, high quality standards, specially regulated
conditions for drugs production and sale and large invest-
ments into research and development (sometimes over 100Strana 602 VOJNOSANITETSKI PREGLED Volumen 70, Broj 6
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million dollars need to be invested to develop a new drug) 
10.
This was a decisive reason why the pharmaceutical industry
put the pressure to obtain the patent protection of newly in-
vented drugs securing the exclusive rights for their commer-
cial exploitation. In this way they could ensure return to in-
vestment and profit gain that can further be reinvested into
new research cycles. The opponents of the patent protection
for pharmaceutical products underline the special purpose of
these products – health maintenance and protection. Pointing
out that pharmaceutical products assist in maintaining the
functions of vital life, they believe that the inventions in this
field are for public good and should be made available to en-
tire mankind without patent restrictions. Yet, the opinion of
those who advocate the awarding of patent rights for phar-
maceutical products has prevailed and possibility of patent
protection for these products are envisaged by the 1973 EPC
and the 1995 Agreement on Trade-Related Aspects of Intel-
lectual Property Rights (TRIPS). Patent rights awarding for
inventions of drugs has contributed to further boost of this
industry and its high profitability.  The patented drugs are
more expensive, yet it has been estimated that 65% of phar-
maceutical substances would have never been developed if
the drugs were not allowed patent protection 
13.
In our country, in spite of big resistance of the pharma-
ceutical industry in former Yugoslavia, patent rights were
granted to the inventors of pharmaceutical products under the
1990 Law amending and modifying the former federal 1981
Law on the protection of inventions, technical improvements
and distinctive signs 
14. However, in order to allow the na-
tional pharmaceutical industry to adjust to the new strategic
orientation of technological development, granting of patent
rights for drug inventions was delayed until December 31,
1992.  Despite the advantages offered by this law, our phar-
maceutical industry continued to produce mostly generic
medical products 
15 that cannot be patented. These are the
drugs and medicines which contain the same active ingredi-
ent as the original medical products, thus having the same ef-
fect as the original drugs.  However, since the original drug
is the subject of patent protection, a generic drug is launched
to the market after the expiration of the original drug’s pat-
ent. Generic drugs are, therefore, cheaper although their
quality, efficacy and safety should not lag behind those of
the original drugs. From the abovementioned, it can be con-
cluded that since generic medical drugs do not represent
newly invented products, they cannot be the subject of patent
protection
16.
Curative substances can be obtained from natural
sources by applying isolation or purification methods or in a
biosynthetic way, that is they can be produced according to
previously defined structure of pharmacologically active
molecule or designed according to genomics and goals to be
attained by these medicines 
13. So far several million com-
pounds have been isolated, synthesized and tested for the
purpose of obtaining new drugs 
10.  Yet, in modern pharma-
cology, there is a decreasing number of drugs which are
based on a completely new chemical compound, but rather
on a new formula, composition, production process or appli-
cation of the already known active pharmaceutical ingredi-
ents (API) 
17, 13. The latter (a new application of known API)
means the possibility of obtaining further purpose-related
patent protection for the second and any further more spe-
cific use of an API in surgery, therapy and diagnostic method
since according to article 54 (4) EPC the new use of such
substances and compositions for any such method is not
comprised in the state of art. It is a significant digression
from the corner stone rule of patent law that patents can be
granted for inventions upon which the requirement of abso-
lute novelty is fulfilled. This is the result of the fact that
during the development of pharmaceutical industry, focus
has been placed on the product formulation to secure the op-
timal exploitation of a curative substance (quantity, compo-
sition and form) for treatment and therapeutic purposes 
12.
The patent law theory advocates the thesis that the substance
itself cannot be the subject of patent protection. Nowadays, it
is not difficult to synthesize a new compound, but it is diffi-
cult and extremely expensive to find a medical application
for such a new compound 
14. Sometimes it is necessary to
synthesize hundreds, even thousands of new compounds to
create a new drug 
10. Therefore, the invention of the sub-
stance itself for the purpose of a drug creation is of a secon-
dary importance, which is not the case with other products.
Moreover, in case that the invented substances and not its
application was patented, this would be threaten and hinder
further enhancement of chemical and pharmaceutical indus-
tries
14. On the other side, a patent protection of the applica-
tion of the invented curative substance is quite justifiable.
Therefore, it can be said that patent law allows the protection
of the invented substance or composition in its technical
form, to be applied during surgery, therapy or diagnostic
methods under the condition that these curative substances
are applied for new purposes which have never been indi-
cated before 
18.
The extension of the patent protection term for the
inventions of human and animal drugs
Human or animal drug is a product which is found on
the market in a certain dosage, pharmaceutical form and
package containing the substance or a combination of sub-
stances  which have been proven to be effective in treatment,
cure or prevention of  disease in humans, or animals, that is
the substance or a combination of substances  which can be
used in humans and animals either for the purpose of estab-
lishing diagnosis or for the purpose of restoring, improving
or changing a physiological function in humans or animals
by means of pharmacological, immunological or metabolic
effects of that drug 
19. Patent rights awarded for drug inven-
tion fall in domain of property rights, that is, private rights.
However, given the general purpose of drugs, this field re-
flects strong public interest. It is of public interest that sub-
stances and compositions declared as drugs are safe for hu-
man and animals’ health. Obtaining the patent protection for
a certain pharmaceutical product means that that product is
new, having an inventive step and can be applied in industry.
However, granting patent rights for a newly invented drug is
not a guarantee that this new, inventive substance or compo-
sition, applicable in industry, could not adversely affect one'sVolumen 70, Broj 6 VOJNOSANITETSKI PREGLED Strana 603
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health. Since this kind of testing is not performed during the
patent administrative procedures, it is necessary to evaluate
that the invented human or animal drug (or plant protection
product) is “safe for humans, animals and plants before it is
launched for sale” 
20.  Only after it has been confirmed that
the invented product does not represent health hazard, the in-
ventor, that is the holder of patent rights for this drug, is al-
lowed to start its production and sale. In our country the
Medicines and Medical Devices Agency of Serbia is the final
authority charged for issuing permissions to put of solely
quality, safe and efficacious medicinal products and medical
devices to market.
Setting up the condition that a human or animal drug
needs an authorization issued by  a relevant government
body before being put into production or sold means that
obtaining  the patent rights for that product is not enough and
that it cannot be commercially exploited  before completing
the authorization procedure. Sometime this means that, in
addition to obtaining a necessary production license, the en-
tire administrative procedure for a new drug to be approved
may last for several years. Since the term of patent protection
nevertheless elapses, it can expire even before the inventor
has gained any profit from the patented drug. This can ad-
versely affect the possibility of profit return on investment
and discourage future investment and research efforts in this
field. In order to compensate the inventors and the holders of
patent rights for this loss of time in the term of patent pro-
tection for human and animal drugs, which are the subject of
mandatory approval by a relevant state agency, they are enti-
tled to an additional legal protection in the form of a Sup-
plementary Protection Certificate.
The supplementary protection certificate is a sui generis
industrial property right. The legal powers of supplementary
protection certificate and patent are equal, but supplementary
protection certificate is not granted for all inventions but
only for inventions of drugs for humans and animals and
plant protection products such as insecticides and herbicides
for which to be put to commercial circulation a prior official
authorization has to be secured. Since there are some kinds
of these products which do not require a prior regulatory ap-
proval (galenic medicines, traditional herbal medicines, ac-
tive substances used in drug production, etc), the inventions
of such products cannot be the subject of additional legal
protection by the supplementary protection certificate.
The supplementary protection certificate as a patent law
institute was first introduced in the US patent law in 1984, in
Japanese patent law in 1987, while in EU it was recognized
following the adoption of the Regulation No. 1762/92 by the
Council of EU on June 18, 1992. Since originally this Regu-
lation referred only to pharmaceutical products, the Council
of EU adopted a new Regulation No. 1610/96 on June 23,
1996 extending the possibility of granting the supplementary
protection certificate for inventions of plant protection prod-
ucts
15. In the Republic of Serbia it was first time laid down
by the 1994 Patent Act. According to Serbian law, in order to
grant the supplementary protection certificate, it is necessary
to fulfill the following preconditions: human or animal drug
or plant protection product is covered by a valid patent; there
is a valid authorization issued for that product; human or
animal drug or plant protection product has never been the
subject of a supplementary protection certificate; patent ap-
plication is submitted after January 1993; first official
authorization to put the product into market is issued after
January 2005.
The procedures for granting the supplementary protec-
tion certificate (as well as for the termination of these rights)
are guided by the same provisions for granting the patents. In
order to be granted by a supplementary protection certificate,
the original inventor, that is the holder of the patent rights for
the relevant human or animal drug (or the plant protection
product) or his successor in title,  needs to file the application
within six months from the date of receiving the marketing
permission for that product. If this permission was issued be-
fore granting the patent rights, then the application has to be
filed within 6 months from the date of the official publication
of the patent rights.  Application includes: a written request
for granting the certificate; the data on the per-
son/organization submitting the request (name and address);
the data on the legal representative (name and address); the
number of the original patent and the full name of the inven-
tion; the number and date of issue of the first marketing
authorization or the note stating that the product has already
been the subject of a supplementary protection certificate; a
copy of the marketing authorization issued by a relevant
government body; if such a marketing authorization is not
the first one, then the proof of the product’s identity, the in-
formation on the procedures conducted for its granting, and
the official journal in which the information on the market-
ing authorization was published.
The data submitted in the application for granting the
supplementary protection certificate are filed in the Register
of supplementary protection certificates and published in the
Intellectual Property Journal within six months from the ap-
plication date. This means that within these six months the
application has to be formally evaluated, which includes the
following checking: that the application was submitted in the
required form and contains all required information; that the
application was submitted within legally prescribed time
frame; that all the required documents were enclosed; that
the patent was still valid in time of submitting the application
for the supplementary protection certificate.
Having confirmed that application for the supplemen-
tary protection certificate has been formally and technically
valid, the reviewers proceed with the evaluation of its con-
tent to determine: that all the preconditions prescribed by
substantial law (valid on the date of the application submis-
sion) have been met for granting the supplementary protec-
tion certificate;  that the product for which the supplementary
protection certificate has been filed is patent protected; that
the marketing authorization has been issued in an adequate
manner;  that the product has not  been the subject of a sup-
plementary protection certificate.
Having been confirmed that all the preconditions pre-
scribed by substantial law have been met for granting the
supplementary protection certificate, a formal decision on
accepting the application and granting the supplementaryStrana 604 VOJNOSANITETSKI PREGLED Volumen 70, Broj 6
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protection certificate is issued and the data from the granted
certificate are published in the Official Journal of the Intel-
lectual Property Office. The holder of the supplementary
protection certificate is entitled to supplementary protection
of the patent rights for the period which is equal to the period
that has lapsed from the date of submitting the patent appli-
cation to the date of receiving the first approval for product
marketing, less five years (even such a shortened period of
certificate duration cannot exceed five years from the date of
granting the supplementary protection certificate). Since this
certificate is valid from the date of the expiring of basic pat-
ent rights, it means that the entire patent protection period for
inventions of human and animal drugs and products for plant
protection can be extended to 25 years.
Granting the supplementary protection certificate favors
the interests of pharmaceutical companies which produce
original drugs and medicines. In order to decrease negative
consequences of introducing the institution of the supple-
mentary protection certificate in the domestic pharmaceutical
industry which mostly produces generic drugs and medi-
cines, the application of the legal provisions related to the
supplementary protection certificate was postponed July 1,
2013.
Legal considerations
In conformity in classical patent law doctrine, the in-
ventions related to drugs are not appropriate for patent pro-
tection. These products are vital for the preservation of basic
life functions and therefore, their inventions have been con-
sidered as public good which means that the consumption of
the good by one individual cannot be exclusive and patent
protected, thus reducing availability of the good for con-
sumption by others. The remainders of these traditional pat-
ent law theories can be still found in modern patent law pro-
visions related to the exclusion of surgery, therapy and diag-
nostic methods inventions performed on living people and
animals from patent protection. Although one may consider
that exclusion from patentability of inventions of surgery,
therapy and diagnostic methods is senseless since inventions
of substances, compositions and other products used in those
medical methods are patentable, this legal solution still may
be deemed as justified. There are more reasons for that. The
most important is that the legal status of pharmaceutical
companies and doctors is very different. Pharmaceutical
companies are business operators which produce and sell
goods on the market and at the same time compete with other
pharmaceutical companies in attracting customers. They
have to innovate to survive. Investments in R&D are tremen-
dous and patent protection is necessary to ensure return of
invested capital creating monopolistic market position.
Doctors are employed or self-employed high educated pro-
fessionals who devoted themselves to help people. They are
not business operators and do not do business to obtain profit
but do their job enjoying personal satisfaction, kudos and re-
spect
21. For mentioned they do not need legally guaranteed
market monopoly but conditions to improve their practice
and competencies. In contrary doctors would long time ago
form a lobby strong enough to procure patentability of in-
ventions of medical methods. There is one more important
rationale pro exclusion. On the one hand, completely differ-
ent from the pharmaceutical companies who deal with inter-
posers (drug stores) that is pure commercial activity, doctors
perform some kind of public service 
22 applying their profes-
sional knowledge directly on patients at the time of urgency.
On the other hand, patent protection of drugs, medicines and
other products used in medical procedures is not of an abso-
lute character. Immediate and individual preparation of
medicine in the pharmacy by virtue of presented prescription
is excluded from the legal effect of patent. Surgery, diagnos-
tic and therapy are naturally immediate and individual treat-
ment and such exclusionary situation is constantly present in
doctors' activity. The fact of emergency also makes acquisi-
tion of license uncertain. From the same reason, in the case
of patent abuse, acquisition of compulsory license is impos-
sible because the legal procedure for that lasts too long.
There are more other argumentation in favor of existing legal
solution
23, especially the possibility of moral dilemmas ap-
pearing (save life and risk trial or left patient to die).
One may accept exclusion for inventions of surgery,
therapy and diagnostic methods performed on the human
body but not on animals. Out of any discussion regarding the
animals' position in nutrition chain and its meaning for hu-
man health, looking strict legally, existing legal solution is in
compliance with the ratio of the 2009 Act on Animal Well-
being and overall trends in legal protection of animals.
Conclusion
Although the introduction of patent protection for
drugs, medical means and other products used in medical
methods brought in a mess and confusion in the basis of the
classical patent law theory, the exception from the patent-
ability of methods for treatment of the human or animal
body by surgery or therapy and diagnostic methods prac-
ticed on the human or animal body still may be deemed
justified.
As for the patent protection of drugs, we could discern
two specific characteristics of patent law. The first is related
to the possibility to grant patent rights for the new medical
application (use) of already known product, and the other is
related to the introduction of the supplementary protection
certificate which allows the extension of the protection term
for up to five years.
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